Compare CODI & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CODI | OCGN |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 480.8M | 419.8M |
| IPO Year | N/A | 2014 |
| Metric | CODI | OCGN |
|---|---|---|
| Price | $10.30 | $1.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $9.25 | ★ $9.75 |
| AVG Volume (30 Days) | 798.4K | ★ 9.4M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.25 | $1,718.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.58 | $0.93 |
| 52 Week High | $12.64 | $2.73 |
| Indicator | CODI | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 49.49 | 44.54 |
| Support Level | $9.70 | $1.32 |
| Resistance Level | $11.85 | $1.58 |
| Average True Range (ATR) | 0.59 | 0.09 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 30.51 | 7.14 |
Compass Diversified Holdings is a diversified business conglomerate based in the United States having two groups: branded consumer business and industrial business. Branded consumer businesses are characterized as those businesses that capitalize on a valuable brand name in their respective market sector. It includes 5.11, Ergobaby, Liberty Safe, and Velocity Outdoor. Industrial businesses are characterized as those businesses that focus on manufacturing and selling particular products and industrial services within a specific market sector. The company has operations in the United States, Canada, Europe, Asia Pacific, and other International areas.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").